Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

  • STATUS
    Recruiting
  • End date
    Dec 25, 2026
  • participants needed
    104
  • sponsor
    Peking University
Send
Updated on 25 January 2021
See if I qualify
platelet count
cancer
ejection fraction
breast cancer
neutrophil count
HER2
trastuzumab
bisphosphonate
invasive breast cancer
inflammatory breast cancer
pyrotinib

Summary

This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate (pCR) for adenocarcinoma.

Description

This study is a single-arm, open, phase II clinical study. The subjects are patients with locally advanced, inflammatory, or early HER2-positive breast cancer. The patients enter the trial period after signing informed consent. This study aims to evaluate trastuzumab The pathological complete response rate (pCR) of anti-combined pyrrotinib and chemotherapy (TCbH+Py) in the treatment of HER2-positive breast cancer.

The subjects began to take continuous medication after joining the group, and the total duration of medication was 6 cycles. Three to four weeks after the end of treatment, the surgeon will choose radical mastectomy, modified radical mastectomy or breast-sparing surgery according to the individual conditions of the patient. Regardless of whether the pCR is achieved, the adjuvant trastuzumab therapy or trastuzumab plus pertuzumab therapy is continued after the operation, and the total course of anti-HER2 therapy is up to 1 year (about 18 treatment cycles). According to the clinical stage and molecular classification of the tumor, it is necessary to decide whether adjuvant radiotherapy, chemotherapy and endocrine therapy are needed.

After the subject finishes all treatments, the subjects who are out of the group for non-PD and non-death causes need to receive the validity Follow-up until PD, start receiving other anti-tumor drug treatment or death (whichever comes first).

Details
Condition HER2 Positive Breast Cancer, her2/neu-positive breast cancer, her2-positive breast cancer
Treatment Trastuzumab combined with Pyrotinib and chemotherapy
Clinical Study IdentifierNCT04481932
SponsorPeking University
Last Modified on25 January 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Are you female?
Do you have HER2 Positive Breast Cancer?
Do you have any of these conditions: her2-positive breast cancer or HER2 Positive Breast Cancer or her2/neu-positive breast cancer?
Female between 18 and 70 years old
Histologically confirmed as invasive breast cancer
ECOG PS 0-1
The expected survival time is not less than 12 weeks
Standard immunohistochemical HER2-positive breast cancer patients (IHC +++ or FISH amplification)
The status of hormone receptors (ER and PR) can be known
Clinical examination or imaging examination of primary lesion >2cm
Patients who are operable (T2-3, N0-1, M0), locally advanced (T2-3,N2-3, M0 or T4A-C, any N, M0) or inflammatory breast cancer (T4d, any N, M0) and who have not received any previous anti-tumor therapy (including radiotherapy, chemotherapy, targeted therapy, except those who have received bisphosphonate therapy previously)
Echocardiography indicated left ventricular ejection fraction (LVEF)55%
Adequate organ and bone marrow function, as defined below: a. Neutrophil count (ANC) 1,500/mm3 (1.5 109/L); B. Platelet count (PLT) 100,000/mm3(100 109/L); C. Hemoglobin (Hb) 9 g/dL(90 g/L); D. Serum creatinine 1.5 times upper limit of normal value (ULN) or creatinine clearance 60 ml/min(based on Cockroft - Gault formula); E. Total bilirubin (BIL) 1.5 times the upper limit of normal value (ULN); F. AST/SGOT or ALT/SGPT 2.5 times upper limit of normal value (ULN);G. Urinary protein <2+; If urinary protein 2+, 24-hour urinary protein quantification shows protein must1 g or less
I have agreed and signed the informed consent, and am willing and able to comply with the planned visit, research treatment, laboratory examination and other test procedures

Exclusion Criteria

Have received any previous anti-tumor treatment for primary invasive breast cancer
Previous (<10 years) or other malignant tumors, except for curable cancer species: a. basal cell carcinoma of skin and squamous cell carcinoma b. Carcinoma in situ of cervix
For patients with other malignancies, they can also be included in the study if the time from diagnosis to enrollment exceeds 10 years; Prior surgical treatment is permitted except for radiotherapy or systemic therapy (chemotherapy or endocrine therapy)
Metastatic breast cancer (M1), bilateral or ipsilateral multifocal breast cancer
Uncontrolled hypertension, systolic blood pressure > 150 MMHG and/or diastolic blood pressure > 100 MMHG), or clinical symptomatic cardiovascular disease, myocardial ischemia and myocardial infarction, severe/unstable angina, poor control of cardiac arrhythmias (including women according to Bazett formula correction QTc interphase < 470 ms), symptoms of congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic cerebral embolism), NYHA magnitude cardiac insufficiency
Receive other anti-tumor treatments within 4 weeks before enrollment
Inability to swallow, intestinal obstruction or other factors affecting the use and absorption of medication
Persons with allergic constitution or known history of allergy to the drug components of the program
The patient has a severe concomitant disease or other conditions that the researcher considers inappropriate for the patient to participate in the studyIn any case
Non-surgically sterilized female patients of childbearing age must have negative serum or urine HCG tests within 14 days prior to study inclusion; And must be non-lactation
Other circumstances deemed inappropriate for inclusion by the researcher
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

platelet count
cancer
ejection fraction
breast cancer
neutrophil count
HER2
trastuzumab
bisphosphonate
invasive breast cancer
inflammatory breast cancer
pyrotinib

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note